The global progesterone market, critical for fertility treatments and hormonal disorders, is set to experience significant growth. The market value is predicted to rise from USD 1.12 billion in 2023 to USD 3.38 billion by 2032, displaying a 13.2% CAGR. This growth is largely attributed to the increasing incidence of hormonal disorders, the growing demand for fertility treatments, and the acceptance of injectable and natural progesterone formulations. North America currently holds a significant share in the market, but the Asia-Pacific region is also expected to show substantial growth. Companies like Aquatic Remedies Pvt. Ltd., Bionpharma Inc., and Teva Pharmaceuticals play a pivotal role in this market, focusing on women’s health, fertility, and hormone therapy needs.